 Paroxetine
"Paroxetine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A serotonin uptake inhibitor that is effective in the treatment of depression.
| Descriptor ID |
D017374
|
| MeSH Number(s) |
D03.383.621.600
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Paroxetine".
Below are MeSH descriptors whose meaning is more specific than "Paroxetine".
This graph shows the total number of publications written about "Paroxetine" by people in Harvard Catalyst Profiles by year, and whether "Paroxetine" was a major or minor topic of these publication.
Below are the most recent publications written about "Paroxetine" by people in Profiles.
-
Mills EJ, Ioannidis JP, Thorlund K, Schünemann HJ, Puhan MA, Guyatt GH. How to use an article reporting a multiple treatment comparison meta-analysis. JAMA. 2012 Sep 26; 308(12):1246-53.
-
Komaroff AL. Ask the doctor. I have been taking an SSRI (paroxetine HCI) for many years for chronic anxiety and, at times, panic attacks. What are the side effects of the long-term use of SSRIs? Harv Health Lett. 2012 Aug; 37(10):2.
-
Wahl PM, Gagne JJ, Wasser TE, Eisenberg DF, Rodgers JK, Daniel GW, Wilson M, Schneeweiss S, Rassen JA, Patrick AR, Avorn J, Bohn RL. Early steps in the development of a claims-based targeted healthcare safety monitoring system and application to three empirical examples. Drug Saf. 2012 May 1; 35(5):407-16.
-
Tatonetti NP, Denny JC, Murphy SN, Fernald GH, Krishnan G, Castro V, Yue P, Tsao PS, Tsau PS, Kohane I, Roden DM, Altman RB. Detecting drug interactions from adverse-event reports: interaction between paroxetine and pravastatin increases blood glucose levels. Clin Pharmacol Ther. 2011 Jul; 90(1):133-42.
-
Fang Y, Yuan C, Xu Y, Chen J, Wu Z, Cao L, Yi Z, Hong W, Wang Y, Jiang K, Gao K, Cui X, Nierenberg AA. Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population. J Clin Psychopharmacol. 2010 Aug; 30(4):357-64.
-
Thase ME, Nierenberg AA, Vrijland P, van Oers HJ, Schutte AJ, Simmons JH. Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression. Int Clin Psychopharmacol. 2010 Jul; 25(4):189-98.
-
Schneeweiss S, Patrick AR, Solomon DH, Mehta J, Dormuth C, Miller M, Lee JC, Wang PS. Variation in the risk of suicide attempts and completed suicides by antidepressant agent in adults: a propensity score-adjusted analysis of 9 years' data. Arch Gen Psychiatry. 2010 May; 67(5):497-506.
-
Schneeweiss S, Patrick AR, Solomon DH, Dormuth CR, Miller M, Mehta J, Lee JC, Wang PS. Comparative safety of antidepressant agents for children and adolescents regarding suicidal acts. Pediatrics. 2010 May; 125(5):876-88.
-
Papakostas GI, Charles D, Fava M. Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorder. World J Biol Psychiatry. 2010 Mar; 11(2 Pt 2):300-7.
-
Ghasemi M, Montaser-Kouhsari L, Shafaroodi H, Nezami BG, Ebrahimi F, Dehpour AR. NMDA receptor/nitrergic system blockage augments antidepressant-like effects of paroxetine in the mouse forced swimming test. Psychopharmacology (Berl). 2009 Oct; 206(2):325-33.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|